SCHEMBL3027675

SCHEMBL3027675

Cc1nc(Cl)c(C(=O)NCc2ccc(Cl)c(Oc3cc(C#N)cc(C(F)(F)F)c3)c2F)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
DDR1 Q08345 2/20 0.36
PTGES O14684 7/20 0.35
EPHX2 P34913 2/20 0.34
P2RX7 Q99572 2/20 0.33
HTR2A P28223 1/20 0.32
SLC6A4 P31645 1/20 0.32
KCNH2 Q12809 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
EPAS1 Q99814 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13217775 0.93 CYP3A4 (0.43) CYP3A4CYP2C9CYP2C19DDR1PTGES
SCHEMBL3025466 0.91 CYP3A4 (0.41) CYP3A4CYP2C9CYP2C19DDR1PTGES
SCHEMBL3034593 0.90 CYP3A4 (0.46) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3017381 0.90 CYP3A4 (0.49) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3796786 0.90 CYP3A4 (0.53) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL13634086 0.90 CYP3A4 (0.46) CYP3A4CYP2C9CYP2C19PTGESEPHX2
Trifluoroacetic Acid SCHEMBL3027802 0.90 CYP3A4 (0.41) CYP3A4CYP2C9CYP2C19DDR1PTGES
Trifluoroacetic Acid SCHEMBL3023663 0.89 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19PTGESEPHX2
Trifluoroacetic Acid SCHEMBL13560603 0.89 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3016690 0.89 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19PTGESEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP3A4 169/4885CYP2C9 720/4885CYP2C19 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.